cidara therapeutics press enter to begin your search home about about cidara management team board of directors partnership inquiries careers pipeline overview cd iv cd publications cloudbreak™ opportunity systemic fungal infections systemic candida infections invasive aspergillosis gramnegative bacterial infections newsroom investors overview financials stock information corporate governance news  events shareholder services new hope for serious infections cidara is a clinicalstage biotechnology company focused on the development of new antiinfectives that have the potential to transform the standard of care and save or improve patients’ lives our pipeline includes cd iv a longacting echinocandin antifungal and cd our lead antimicrobial candidate for multidrug resistant bacteria generated by our cloudbreak™ immunotherapy discovery platform about cidara  drug candidates recent news and insights jeff stein and others explore the antifungal public health crisis and the need for nextgeneration antifungal treatments at the bio international convention cidara to participate in antiinfectives panel discussion at the  infectious diseases summit  july   cidara to participate in the  bio international convention  june   view all news releases our mission cidara seeks to save or improve patients’ lives through the development of antiinfectives that transform the standard of care our initial portfolio is comprised of proprietary product candidates for the treatment of serious fungal and bacterial infections there is an urgent and growing need not only for improved antiinfectives but also for entirely new therapeutic approaches to treat and prevent fungal bacterial and viral pathogens particularly those that are increasingly resistant to available treatments cd iv cd iv is a novel echinocandin antifungal with potent activity against candida aspergillus and pcp we are developing cd iv for once weekly use in treatment and prophylaxis we are currently conducting an international phase  trial strive in candidemia and invasive candidiasis learn more cloudbreak™  cd cloudbreak is a proprietary immunotherapy discovery platform that has the potential to do for infectious disease what immunotherapy has done for cancer cd is our lead cloudbreak candidate intended to direct a patient’s immune cells to attack bacterial infections cd  cloudbreak get important news and updates by email about us cidara is a clinicalstage biotechnology company focused on developing new antiinfectives and immunotherapies that have the potential to transform the standard of care and save or improve patients lives learn more  recent newscidara therapeutics to participate in antiinfectives panel discussion at the  infectious diseases summit july  cidara therapeutics to participate in the  bio international convention june   navigationabout cidara cd iv cd cloudbreak™ platform publications investors contact contact us cidara therapeutics inc  nancy ridge drive suite  san diego ca  tel   email infocidaracom   cidara therapeutics inc  terms of use  privacy policy quick linksabout cidara cd iv cd cloudbreak™ platform publications investors contact tweets by cidarathera management team – cidara therapeutics press enter to begin your search home about about cidara management team board of directors partnership inquiries careers pipeline overview cd iv cd publications cloudbreak™ opportunity systemic fungal infections systemic candida infections invasive aspergillosis gramnegative bacterial infections newsroom investors overview financials stock information corporate governance news  events shareholder services management team menuabout cidaramanagement teamboard of directorspartnership inquiriescareers view profile  linkedin jeffrey stein phd president and chief executive officer dr stein has been president ceo and director of cidara since january  previously he was ceo of trius therapeutics inc from  until its acquisition by cubist pharmaceuticals inc in september  during his tenure trius developed the antibacterial drug tedizolid which received marketing approval from the us food and drug administration in june  tedizolid is now marketed by merck under the name sivextro dr stein currently serves as a director of paratek pharmaceuticals nasdaq prtk and ideaya biosciences he is also founding chairman and president of the antibiotics working group an industry leading c organization previously dr stein was a venture partner and kauffman fellow with sofinnova ventures and opened the firm’s san diego office in  prior to joining sofinnova ventures dr stein was cofounder and chief scientific officer of quorex pharmaceuticals which was acquired by pfizer pharmaceuticals in  he has also served as a principal scientist with diversa corporation and the agouron institute dr stein conducted his postdoctoral research as an alexander hollaender distinguished postdoctoral fellow at the california institute of technology and his graduate work as a nasa graduate student researcher fellow at the university of california san diego view profile  linkedin taylor sandison md mph chief medical officer dr sandison has been with cidara since october  he has extensive experience in antiinfective clinical trials and drug development in both academia and industry prior to joining the company he served as senior medical director at merck and prior to that held the same position at cubist pharmaceuticals inc dr sandison has also held positions at trius therapeutics and novartis diagnostics and served as a member of the faculty in the department of medicine at both stanford university and the university of washington he received bs and ba degrees from dartmouth college md and mph degrees from the university of washington and a diploma in tropical medicine and hygiene dtmh from the london school of hygiene and tropical medicine he completed internal medicine residency training at the university of colorado and infectious diseases fellowship training at the university of washington dr sandison currently holds board certifications in infectious diseases and internal medicine view profile  linkedin ken bartizal phd chief development officer dr bartizal has over  years of antiinfective drug discovery evaluation and development experience in the pharmaceutical industry from  to  he served as the chief development officer of trius therapeutics where he led the development of tedizolid phosphate sivextro from preind to nda filing until the acquisition of trius by cubist pharmaceuticals inc prior to joining trius dr bartizal was the executive director and head of infectious diseases at merck while at merck dr bartizal contributed to the development of caspofungin acetate cancidas the first echinocandin antifungal from discovery to market similarly he oversaw nonclinical developmental for ertapenem invanz merck’s carbapenem antibiotic for antibioticresistant bacteria and was a major contributor to ind and nda filings at merck he also brought to clinical development an azalide antibiotic gamithromycin zactran for animal health treatment of bovine respiratory disease and a semisynthetic insecticide for oral treatment of flea and tick infestations in companion animals dr bartizal started his pharmaceutical career at pfizer central research in antibiotic drug discovery dr bartizal received his bs ms and phd degrees from the university of notre dame view profile  linkedin paul daruwala chief commercial officer mr daruwala has over  years of experience in the biopharmaceutical industry and leads cidara’s commercial strategy medical affairs and corporate communications prior to joining cidara mr daruwala was at bristolmyers squibb company where he served as vice president of the us viral hepatitis franchise and was responsible for leading the us launch in hcv and running the hbv business for baraclude prior to bristolmyers squibb mr daruwala served as vice president commercial  strategic management at vertex pharmaceuticals where he helped lead the us launch of incivek for hcv at the time incivek became the fastest drug launch to achieve blockbuster status mr daruwala had previously spent  years at merck in us and global commercial leadership roles in antivirals antifungals antiinflammatory products business development managed markets and sales management among these he led the global commercialization efforts for the first approved echinocandin antifungal drug caspofungin acetate cancidas paul received his degree in pharmacy from the university of kentucky view profile  linkedin kevin forrest phd chief strategy officer dr forrest was founding cfo and coo and is a cofounder of cidara therapeutics as well as coinventor of the company’s cloudbreak™ antiinfective immunotherapy platform from  to  dr forrest held positions of increasing responsibility at am ventures an early stage life science venture capital firm while at am dr forrest led or supported investments in relypsa flexion therapeutics semprus biosciences acquired by teleflex and marcadia biotechnologies acquired by roche among others dr forrest has served as a review member of the princeton university ip accelerator fund and leads organization of the revolution symposium a leading meeting for heads of life science rd dr forrest holds a bs in biology from boston college and phd in molecular biology from princeton university view profile  linkedin neil abdollahian chief business officer mr abdollahian has over  years of corporate strategy partnering and ma experience in the biopharmaceutical industry and leads cidara’s business development strategy and execution prior to joining cidara mr abdollahian was managing director of clarity point partners a strategic advisory firm focused on managing corporate licensing efforts product acquisitions and technology spinouts for a number of biopharmaceutical companies from  to  he served as vice president of corporate development at trius therapeutics where he led the corporate partnering initiatives that resulted in the asiapacific and emerging markets strategic partnership with bayer healthcare and ultimately the acquisition by cubist pharmaceuticals in  in  mr abdollahian served as director of special projects in a biopharmaceutical focused investment bank in sydney australia and from  to  he held various business development positions focused on closing highvalue transactions while at avanir pharmaceuticals isis pharmaceuticals and neurogen corporation mr abdollahian holds an mba from pepperdine university an ms in the biomedical sciences from the university of new mexico medical school and a bs in biology from the george washington university view profile  linkedin matt onaitis jd chief financial officer general counsel and secretary mr onaitis brings a wealth of public company general counsel experience to cidara prior to joining cidara mr onaitis was general counsel and secretary of ignyta previously he was general counsel and secretary of trius therapeutics inc from may  through its acquisition by cubist pharmaceuticals inc in september  following the acquisition mr onaitis remained with cubist assisting with the integration through december  mr onaitis was senior vice president general counsel and secretary at somaxon pharmaceuticals from may  through somaxon’s acquisition by pernix therapeutics holdings in march  prior to somaxon mr onaitis served as associate general counsel at biogen idec as director legal affairs at elan corporation and in private practice specializing in corporate and commercial law mr onaitis is a director of snp bio inc mr onaitis holds a jd from stanford law school and a bs in mechanical engineering from carnegie mellon university view profile  linkedin james m balkovec phd senior vice president research dr balkovec has over  years of experience in the pharmaceutical industry and has a broad background in drug discovery prior to joining cidara he was an industry consultant in early stage programs specializing in antiinfectives at merck laboratories he was senior scientific director and team leader overseeing programs in infectious disease metabolic syndrome inflammatory and thrombosis disease during his tenure he brought forward over a dozen development candidates dr balkovec led the discovery efforts and is a coinventor of the first approved echinocandin antifungal caspofungin acetate cancidas and is responsible for the first orally active gs inhibitor currently in clinical development dr balkovec led a number of early stage discovery programs and is an author or inventor on over  publications and patents dr balkovec has received several prestigious awards including the american chemical society’s heroes of chemistry award he currently serves on the scientific advisory board of a private company focused on small molecule therapeutics and as a local councilor for the american society for microbiology dr balkovec received his phd in organic chemistry at the university of wisconsin in madison working under barry trost and was an nih postdoctoral fellow with gilbert stork at columbia university get important news and updates by email about us cidara is a clinicalstage biotechnology company focused on developing new antiinfectives and immunotherapies that have the potential to transform the standard of care and save or improve patients lives learn more  recent newscidara therapeutics to participate in antiinfectives panel discussion at the  infectious diseases summit july  cidara therapeutics to participate in the  bio international convention june   navigationabout cidara cd iv cd cloudbreak™ platform publications investors contact contact us cidara therapeutics inc  nancy ridge drive suite  san diego ca  tel   email infocidaracom   cidara therapeutics inc  terms of use  privacy policy quick linksabout cidara cd iv cd cloudbreak™ platform publications investors contact tweets by cidarathera about us – cidara therapeutics press enter to begin your search home about about cidara management team board of directors partnership inquiries careers pipeline overview cd iv cd publications cloudbreak™ opportunity systemic fungal infections systemic candida infections invasive aspergillosis gramnegative bacterial infections newsroom investors overview financials stock information corporate governance news  events shareholder services about cidara therapeutics menusummarydevelopment programcd ivcloudbreak™leadership business summary cidara is a clinicalstage biotechnology company focused on developing new antiinfectives that have the potential to transform the standard of care and save or improve patients’ lives the company is currently advancing its novel echinocandin antifungal cd iv through phase  and developing cd its bispecific antimicrobial immunotherapy for the treatment of multidrug resistant gramnegative bacterial infections cd iv has enhanced potency and is the only onceweekly therapy intended for the treatment and prevention of lifethreatening invasive fungal infections cd is the first drug candidate selected from cidara’s novel cloudbreak™ platform the first immunotherapy discovery platform designed specifically to create compounds that direct a patient’s immune cells to attack and eliminate bacterial fungal or viral pathogens cidara is headquartered in san diego california  download highresolution logo pipeline we are developing a balanced pipeline of product and development candidates with a focus on serious fungal and bacterial infections our lead product candidate cd iv is a novel echinocandin antifungal with enhanced potency and the only onceweekly therapy intended for the treatment and prevention of lifethreatening invasive fungal infections in addition we have created our proprietary cloudbreak immunotherapy platform to generate new development candidates that will expand and diversify our pipeline view our pipeline  cd iv cd iv is a novel molecule in the echinocandin class of antifungals we are initially developing cd iv for the treatment of systemic candida infections these infections include candidemia and related cases of invasive candidiasis fungal infections associated with high mortality rates the current treatment alternatives for systemic fungal infections including polyenes azoles and currently approved echinocandins have limitations that may be addressed by novel antifungals despite these limitations annual sales for systemic antifungals are approximately  billion dollars globally cd iv exhibits a high exposure early in the course of infection and prolonged halflife which in contrast to all other echinocandins allows for onceweekly frontloaded iv therapy and convenient outpatient dosing we believe that this pharmacokinetic profile may overcome the limitations of the current standard of care by allowing singleagent treatment in both inpatient and outpatient settings facilitating shorter and less costly hospital stays offering the potential ability to treat lesssusceptible pathogens and enhance tissue penetration at the site of infection providing more convenient outpatient echinocandin treatment and prophylaxis regimens improving compliance for outpatients we have completed two phase  clinical trials for cd iv a single ascending dose trial sad and a multiple ascending dose mad trial we are currently conducting an international phase  clinical trial in candidemia called strive we expect results from this trial in the fourth quarter of  learn more about cd iv  cd iv halflife pk measurements marked with an asterisk are from assays conducted by us other values are from studies published by third parties preclinical and clinical results to date demonstrate that a single dose of cd iv can provide sufficient drug exposure for a period of seven days cloudbreak™ immunotherapy platform our proprietary cloudbreak immunotherapy discovery platform has the potential to do for infectious disease what immunotherapy has done for cancer cloudbreak is a fundamentally new approach for the treatment of infectious disease which redirects the immune system to destroy fungal bacterial and viral pathogens the design of the cloudbreak immunotherapy platform recognizes that most infectious disease is due to a temporary deficiency in the function of the immune system our cloudbreak candidates are designed to address this deficiency by recruiting components of the patient’s immune system to the site of infection cloudbreak supports the engineering of bispecific agents that target the pathogen and prime the immune system to generate a more effective antiinfective response we are developing initial cloudbreak candidates for the treatment of serious gramnegative bacterial infections learn more about the cloudbreak platform  each cloudbreak candidate has two components that are joined by a chemical linker a targeting moiety tm that recognizes a cell surface target and an effector moiety em that is recognized by the immune system the coupling of the tm to the em results in a bispecific molecule that can direct the immune system specifically to the targeted pathogen leadership we have assembled a team of senior executives with significant experience in the antiinfective market and a track record of successfully developing and commercializing many antiinfective products  management team  board of directors jeffrey stein phd president and chief executive officer view profile  linkedin taylor sandison md mph chief medical officer view profile  linkedin ken bartizal phd chief development officer view profile  linkedin paul daruwala chief commercial officer view profile  linkedin kevin forrest phd chief strategy officer view profile  linkedin neil abdollahian chief business officer view profile  linkedin matt onaitis jd chief financial officer general counsel and secretary view profile  linkedin jim balkovec phd senior vice president research view profile  linkedin get important news and updates by email about us cidara is a clinicalstage biotechnology company focused on developing new antiinfectives and immunotherapies that have the potential to transform the standard of care and save or improve patients lives learn more  recent newscidara therapeutics to participate in antiinfectives panel discussion at the  infectious diseases summit july  cidara therapeutics to participate in the  bio international convention june   navigationabout cidara cd iv cd cloudbreak™ platform publications investors contact contact us cidara therapeutics inc  nancy ridge drive suite  san diego ca  tel   email infocidaracom   cidara therapeutics inc  terms of use  privacy policy quick linksabout cidara cd iv cd cloudbreak™ platform publications investors contact tweets by cidarathera pipeline – cidara therapeutics press enter to begin your search home about about cidara management team board of directors partnership inquiries careers pipeline overview cd iv cd publications cloudbreak™ opportunity systemic fungal infections systemic candida infections invasive aspergillosis gramnegative bacterial infections newsroom investors overview financials stock information corporate governance news  events shareholder services cidara is pursuing a balanced infectious diseasefocused development strategy intended to transform standards of care and save lives cd iv candidemia  invasive candidiasis cd multidrug resistant gramnegative bacteria get important news and updates by email about us cidara is a clinicalstage biotechnology company focused on developing new antiinfectives and immunotherapies that have the potential to transform the standard of care and save or improve patients lives learn more  recent newscidara therapeutics to participate in antiinfectives panel discussion at the  infectious diseases summit july  cidara therapeutics to participate in the  bio international convention june   navigationabout cidara cd iv cd cloudbreak™ platform publications investors contact contact us cidara therapeutics inc  nancy ridge drive suite  san diego ca  tel   email infocidaracom   cidara therapeutics inc  terms of use  privacy policy quick linksabout cidara cd iv cd cloudbreak™ platform publications investors contact tweets by cidarathera about us – cidara therapeutics press enter to begin your search home about about cidara management team board of directors partnership inquiries careers pipeline overview cd iv cd publications cloudbreak™ opportunity systemic fungal infections systemic candida infections invasive aspergillosis gramnegative bacterial infections newsroom investors overview financials stock information corporate governance news  events shareholder services about cidara therapeutics menusummarydevelopment programcd ivcloudbreak™leadership business summary cidara is a clinicalstage biotechnology company focused on developing new antiinfectives that have the potential to transform the standard of care and save or improve patients’ lives the company is currently advancing its novel echinocandin antifungal cd iv through phase  and developing cd its bispecific antimicrobial immunotherapy for the treatment of multidrug resistant gramnegative bacterial infections cd iv has enhanced potency and is the only onceweekly therapy intended for the treatment and prevention of lifethreatening invasive fungal infections cd is the first drug candidate selected from cidara’s novel cloudbreak™ platform the first immunotherapy discovery platform designed specifically to create compounds that direct a patient’s immune cells to attack and eliminate bacterial fungal or viral pathogens cidara is headquartered in san diego california  download highresolution logo pipeline we are developing a balanced pipeline of product and development candidates with a focus on serious fungal and bacterial infections our lead product candidate cd iv is a novel echinocandin antifungal with enhanced potency and the only onceweekly therapy intended for the treatment and prevention of lifethreatening invasive fungal infections in addition we have created our proprietary cloudbreak immunotherapy platform to generate new development candidates that will expand and diversify our pipeline view our pipeline  cd iv cd iv is a novel molecule in the echinocandin class of antifungals we are initially developing cd iv for the treatment of systemic candida infections these infections include candidemia and related cases of invasive candidiasis fungal infections associated with high mortality rates the current treatment alternatives for systemic fungal infections including polyenes azoles and currently approved echinocandins have limitations that may be addressed by novel antifungals despite these limitations annual sales for systemic antifungals are approximately  billion dollars globally cd iv exhibits a high exposure early in the course of infection and prolonged halflife which in contrast to all other echinocandins allows for onceweekly frontloaded iv therapy and convenient outpatient dosing we believe that this pharmacokinetic profile may overcome the limitations of the current standard of care by allowing singleagent treatment in both inpatient and outpatient settings facilitating shorter and less costly hospital stays offering the potential ability to treat lesssusceptible pathogens and enhance tissue penetration at the site of infection providing more convenient outpatient echinocandin treatment and prophylaxis regimens improving compliance for outpatients we have completed two phase  clinical trials for cd iv a single ascending dose trial sad and a multiple ascending dose mad trial we are currently conducting an international phase  clinical trial in candidemia called strive we expect results from this trial in the fourth quarter of  learn more about cd iv  cd iv halflife pk measurements marked with an asterisk are from assays conducted by us other values are from studies published by third parties preclinical and clinical results to date demonstrate that a single dose of cd iv can provide sufficient drug exposure for a period of seven days cloudbreak™ immunotherapy platform our proprietary cloudbreak immunotherapy discovery platform has the potential to do for infectious disease what immunotherapy has done for cancer cloudbreak is a fundamentally new approach for the treatment of infectious disease which redirects the immune system to destroy fungal bacterial and viral pathogens the design of the cloudbreak immunotherapy platform recognizes that most infectious disease is due to a temporary deficiency in the function of the immune system our cloudbreak candidates are designed to address this deficiency by recruiting components of the patient’s immune system to the site of infection cloudbreak supports the engineering of bispecific agents that target the pathogen and prime the immune system to generate a more effective antiinfective response we are developing initial cloudbreak candidates for the treatment of serious gramnegative bacterial infections learn more about the cloudbreak platform  each cloudbreak candidate has two components that are joined by a chemical linker a targeting moiety tm that recognizes a cell surface target and an effector moiety em that is recognized by the immune system the coupling of the tm to the em results in a bispecific molecule that can direct the immune system specifically to the targeted pathogen leadership we have assembled a team of senior executives with significant experience in the antiinfective market and a track record of successfully developing and commercializing many antiinfective products  management team  board of directors jeffrey stein phd president and chief executive officer view profile  linkedin taylor sandison md mph chief medical officer view profile  linkedin ken bartizal phd chief development officer view profile  linkedin paul daruwala chief commercial officer view profile  linkedin kevin forrest phd chief strategy officer view profile  linkedin neil abdollahian chief business officer view profile  linkedin matt onaitis jd chief financial officer general counsel and secretary view profile  linkedin jim balkovec phd senior vice president research view profile  linkedin get important news and updates by email about us cidara is a clinicalstage biotechnology company focused on developing new antiinfectives and immunotherapies that have the potential to transform the standard of care and save or improve patients lives learn more  recent newscidara therapeutics to participate in antiinfectives panel discussion at the  infectious diseases summit july  cidara therapeutics to participate in the  bio international convention june   navigationabout cidara cd iv cd cloudbreak™ platform publications investors contact contact us cidara therapeutics inc  nancy ridge drive suite  san diego ca  tel   email infocidaracom   cidara therapeutics inc  terms of use  privacy policy quick linksabout cidara cd iv cd cloudbreak™ platform publications investors contact tweets by cidarathera cidara therapeutics inc private company information  bloomberg july    am et biotechnology company overview of cidara therapeutics inc snapshot people company overview cidara therapeutics inc a biopharmaceutical company focuses on the discovery development and commercialization of novel antiinfectives for the treatment of various diseases its lead product candidate is cd iv a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections the company also develops cd a novel bispecific antimicrobial immunotherapy for the treatment of multidrugresistant gramnegative bacterial infections including those caused by pathogens harboring the mcr plasmid in addition it develops a proprietary immunotherapy technology platform cloudbreak which is designed to create compounds tha cidara therapeutics inc a biopharmaceutical company focuses on the discovery development and commercialization of novel antiinfectives for the treatment of various diseases its lead product candidate is cd iv a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections the company also develops cd a novel bispecific antimicrobial immunotherapy for the treatment of multidrugresistant gramnegative bacterial infections including those caused by pathogens harboring the mcr plasmid in addition it develops a proprietary immunotherapy technology platform cloudbreak which is designed to create compounds that direct immune system to attack and eliminate bacterial fungal or viral pathogens the company was formerly known as k therapeutics inc and changed its name to cidara therapeutics inc in june  cidara therapeutics inc was founded in  and is based in san diego california detailed description  nancy ridge drivesuite san diego ca united statesfounded in  employees phone  wwwcidaracom key executives for cidara therapeutics inc dr jeffrey l stein phd chief executive officer president and executive director age  total annual compensation k dr kevin m forrest phd founder and chief strategy officer age  total annual compensation k mr matthew w onaitis jd chief financial officer general counsel and secretary age  total annual compensation k mr neil abdollahian chief business officer age  total annual compensation k compensation as of fiscal year  cidara therapeutics inc key developments cidara therapeutics inc presents at bio international conference  jun through jun may   cidara therapeutics inc presents at bio international conference  jun through jun venue san diego convention center san diego ca  united states presentation date  speakers jun jeffrey l stein chief executive officer president and executive director jun cidara therapeutics inc announces consolidated unaudited earnings results for the first quarter ended march   may   cidara therapeutics inc announced consolidated unaudited earnings results for the first quarter ended march   for the quarter the company reported loss from operations of  compared with  for the same period a year ago net loss was  compared with  for the same period a year ago basic and diluted net loss per share was  compared with  for the same period a year ago cidara therapeutics promotes taylor sandison to chief medical officer may   cidara therapeutics announced that taylor sandison md mph has been named as chief medical officer cmo of the company dr sandison has been serving as acting chief medical officer of cidara since september  as cmo he will continue to lead the global clinical development of cd iv cidaras novel echinocandin antifungal currently in phase  clinical trials as well as the expanding pipeline of antiinfective candidates generated by the companys cloudbreak immunotherapy platform similar private companies by industry company name region n labs inc united states andme inc united states c tech corporation inc united states v biosciences inc united states bar biologics inc united states recent private companies transactions typedate target private placement october    request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact cidara therapeutics inc please visit wwwcidaracom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close cidara therapeutics inc  cdtx  stock price today  zacks cdtx is down  today but wheres it headed in august privacy policy no cost no obligation to buy anything ever join sign in member sign in keep me signed in what does remember me do forgot password create a new account you are being directed to zackstrade a division of lbmz securities and licensed brokerdealer zackstrade and zackscom are separate companies the web link between the two companies is not a solicitation or offer to invest in a particular security or type of security zackstrade does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating indiv idual securities if you wish to go to zackstrade click ok if you do not click cancel ok cancel back to top more cidara therapeutics inc cdtx delayed data from nsdq  usd     updated jul    pm et add to portfolio zacks rank hold          style scores f value  f growth  d momentum  f vgm the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores industry rank top  out of  industry medical  biomedical and genetics view all zacks  ranked stocks trades from  this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn about the zacks rank zacks rank home  zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank quote overview stock activity open  day low  day high   wk low   wk high  avg volume  market cap  m dividend    beta  key earnings data earnings esp  most accurate est  current qtr est  current yr est  exp earnings date  prior year eps  exp eps growth yrna forward pe na peg ratio na medical » medical  biomedical and genetics zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings research report for cdtx all zacks’ analyst reports news for cdtx zacks news for cdtx other news for cdtx is a surprise coming for cidara therapeutics cdtx this earnings season am est zacks perrigo company prgo q earnings disappointment in store am est zacks cdtx what are zacks experts saying now zacks private portfolio services whats in store for biodelivery bdsi this earnings season am est zacks whats in the cards for ionis ions this earnings season am est zacks  of the best  worst performing drug stocks of q am est zacks more zacks news for cdtx cidara therapeutics to participate in antiinfectives panel discussion at the  infectious diseases summit am est business wire cdtx insiders vs shorts am est market news video premarket analyst action  healthcare am est seeking alpha antimicrobial working group members to participate in  bio international convention panel am est pr newswire healthcare gainers  losers as of  am am est seeking alpha more other news for cdtx premium research for cdtx zacks rank hold  zacks industry rank top  out of  zacks sector rank bottom   out of  style scores f value  f growth  d momentum  f vgm earnings esp  research report for cdtx snapshot this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to get access to the zacks rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the three scores are based on the trading styles of growth value and momentum growth score a value score a momentum score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b zacks style scores education  learn more about the zacks style scores the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports   change in last  days view all zacks rank  strong buys premium research industry analysis top peers symbol zacks rank cidara therapeutics inc cdtx bioverativ inc bivv cellectis sa clls enzo biochem inc enz exelixis inc exel vertex pharmaceuticals incorporated vrtx aveo pharmaceuticals inc aveo see all medical  biomedical and genetics peers price and eps surprise chart  month  months ytd interactive chart  fundamental chart billion dollar secret company summary cidara therapeutics inc is a biotechnology company the company is focused on the discovery development and commercialization of novel antiinfectives its product pipeline includes cd iv a longacting echinocandin antifungal cd topical and c which are in different clinical trial the company developed its product using cloudbreaktm immunotherapy platform cidara therapeutics inc is headquartered in san diego california cidara therapeutics inc  ipo candy skip to primary navigation skip to content becomeamember ipo candyeveryones favorite site for ipo insights and analysismain navigationhome » cidara therapeutics inccidara therapeutics inc  by cidara therapeutics inc a biopharmaceutical company focuses on the discovery development and commercialization of novel antiinfectives for the treatment of diseases its lead product candidate is cd iv a novel molecule in the echinocandin class of antifungals for the treatment and prevention of systemic candida infections the company also develops cd topical a topical formulation of cd for the treatment of recurrent vulvovaginal candidiasis a prevalent mucosal infection in addition it develops a proprietary immunotherapy technology platform cloudbreak which is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease cidara therapeutics is developing its first cloudbreak development candidate c for the treatment of invasive aspergillosis and evaluating additional opportunities to expand its cloudbreak immunotherapy platform to other areas of infectious disease the company was formerly known as k therapeutics inc and changed its name to cidara therapeutics inc in june  cidara therapeutics inc was founded in  and is based in san diego california cidara therapeutics inc cidara therapeutics inc a biopharmaceutical company focuses on the discovery development and commercialization of novel antiinfectives for the treatment of diseases its lead product candidate is cd iv a novel molecule in the echinocandin class of antifungals for the treatment and prevention of systemic candida infections the company also develops cd topical a topical formulation of cd for the treatment of recurrent vulvovaginal candidiasis a prevalent mucosal infection in addition it develops a proprietary immunotherapy technology platform cloudbreak which is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease cidara therapeutics is developing its first cloudbreak development candidate c for the treatment of invasive aspergillosis and evaluating additional opportunities to expand its cloudbreak immunotherapy platform to other areas of infectious disease the company was formerly known as k therapeutics inc and changed its name to cidara therapeutics inc in june  cidara therapeutics inc was founded in  and is based in san diego california twitter facebook google linkedin cidara therapeutics incpcidara therapeutics inc a biopharmaceutical company focuses on the discovery development and commercialization of novel antiinfectives for the treatment of diseases its lead product candidate is cd iv a novel molecule in the echinocandin class of antifungals for the treatment and prevention of systemic candida infections the company also develops cd topical a topical formulation of cd for the treatment of recurrent vulvovaginal candidiasis a prevalent mucosal infection in addition it develops a proprietary immunotherapy technology platform cloudbreak which is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease cidara therapeutics is developing its first cloudbreak development candidate c for the treatment of invasive aspergillosis and evaluating additional opportunities to expand its cloudbreak immunotherapy platform to other areas of infectious disease the company was formerly known as k therapeutics inc and changed its name to cidara therapeutics inc in june  cidara therapeutics inc was founded in  and is based in san diego californiap caunited statesphone  cdtx antiinfective drugs documents roadshow transcript main categoryhealthcare categoriesdrugs contact httpwwwcidaracom  address nancy ridge drive suite  san diego california  united states we love ipos the ipo market provides a magical window into the most exciting technologies emerging consumer trends and important business developments  all testing their mettle in the crucible of the public markets we are constantly learning and researching to deliver the best insights available we are independent we have no vested interests driving our work all the investment banks and brokers on a deal are paid to do a sales and marketing job our job is to remain objective and use a factbased approach to evaluate the potential for an ipo we get the best ratings ipo candy has been recognized since  as the single best place to get commentary analysis and assets in the ipo market the most common writein comment we get from users is that they love what we do we share everything we know with three decades of research under our belt we want to share what we have learned and the best practices we have discovered our ipo university contains texts videos and resources to share our process and help everyone develop their skills become an ipocandy member enjoy the benefits of full access to our content including access to ipo roadshow slideshows and transcripts included in our posts members also get additional insights via email receive our monthly candygram and have access to our ipo calendar become a member cidara therapeutics inc nasdaqcdtx cidara therapeutics inc cdtx product news news  stocknewscom     follow us stocktwits twitter cidara therapeutics inc cdtx product news news cdtx – reports that the phase  radiant clinical trial in acute vulvovaginal candidiasi did not show sufficient efficacy to justify further development feb    am  by stocknewscom staff product news key facts surrounding this news item cdtx had a powr rating of c neutral coming into today cdtx was  above its day moving average coming into today cdtx was  above its day moving average coming into today cdtx was  above its day moving average coming into today cdtx was  above its day moving average coming into today cdtx was  above its day moving average coming into today cdtx had returned  yeartodate leading up to today’s news versus a  return from the benchmark sp  during the same period more info about cidara therapeutics inc cdtx cidara therapeutics inc focuses on the discovery development and commercialization of novel antiinfectives for the treatment of diseases the company was formerly known as k therapeutics inc and changed its name to cidara therapeutics inc in june  the company was founded in  and is based in san diego california view our full cdtx ticker page with ratings news and more cdtx at a glance cdtx current powr rating™ overall powr rating™ cdtx current price   more cdtx ratings data and news cdtx price reaction the day of this event feb  cdtx closing price cdtx volume from avgleading up to this eventcdtx mo returnnaafter this eventcdtx day returncdtx day returncdtx day return cdtx price chart more cidara therapeutics inc cdtx news view all eventdate symbol news detail start price end price change powr rating loading please wait view all cdtx news page generated in  seconds cidara therapeutics k may    pm  seeking alphasign in  join nowgo»cidara therapeutics cdtxform k  current reportmay    pmabout cidara therapeutics cdtxview as pdf cidara therapeutics inc form k received   united states securities and exchange commission washington dc    form k   current report pursuant to section  or d of the securities exchange act of  date of report date of earliest event reported may       cidara therapeutics inc exact name of registrant as specified in its charter       delaware       state or other jurisdiction of incorporation or organization   commission file number   irs employer identification number    nancy ridge drive suite  san diego california    address including zip code and telephone number including area code of registrant’s principal executive offices     check the appropriate box below if the form k filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions   ¨ written communications pursuant to rule  under the securities act  cfr  ¨ soliciting material pursuant to rule a under the exchange act  cfr a ¨ precommencement communications pursuant to rule db under the exchange act  cfr db   ¨ precommencement communications pursuant to rule ec under the exchange act  cfr ec indicate by check mark whether the registrant is an emerging growth company as defined in rule  of the securities act of  §  of this chapter or rule b of the securities exchange act of  § b of this chapter  emerging growth company x if an emerging growth company indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section a of the exchange act ¨  in this report “cidara therapeutics” “cidara” “company” “we” “us” and “our” refer to cidara therapeutics inc item  results of operations and financial condition on may    we issued a press release reporting our financial results for the first quarter ended march     the full text of the press release is attached as exhibit  to this current report on form k in accordance with general instruction b of form k the information contained or incorporated herein including the press release filed as exhibit  shall not be deemed “filed” for purposes of section  of the securities exchange act of  as amended the “exchange act” or otherwise subject to the liabilities of that section nor shall it be deemed to be incorporated by reference into any filing under the securities act of  as amended or the exchange act whether made before or after the date hereof except as expressly set forth by specific reference in such filing to this current report on form k item  financial statements and exhibits d exhibits   exhibit no    description           press release issued may   reporting financial results for the first quarter ended march    signatures pursuant to the requirements of the securities exchange act of  the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized     cidara therapeutics inc       date may     s jeffrey l stein       jeffrey l stein       president and chief executive officer principal executive officer  index to exhibits     exhibit no    description           press release issued may   reporting financial results for the first quarter ended march    exhibit  click to enlarge for immediate release cidara provides corporate update and reports first quarter  financial results san diego may   – cidara therapeutics inc nasdaq cdtx a biotechnology company developing novel antiinfectives including immunotherapies today reported financial results for the three months ended march   and provided an update on its corporate activities and product pipeline “we are excited about the progress we are making on our cd iv and cloudbreak™ programs which we discussed at our recent investor day” said jeffrey stein phd president and chief executive officer of cidara “we anticipate announcing topline data from our strive phase  trial of cd iv in the fourth quarter and are advancing cd through indenabling studies our financial position remains strong and i look forward to providing an update on our continued progress as the year unfolds” first quarter  and subsequent highlights • presented data at eccmid and sid annual meetings in april  cidara presented data from nonclinical studies of its novel echinocandin antifungal cd and its cloudbreak antibacterial immunotherapy cd at the th european congress of clinical microbiology and infectious diseases eccmid in vienna austria and at the  society for investigative dermatology sid annual meeting in portland oregon • awarded grant for up to  million from carbx in march  cidara received a grant for up to  million from carbx combating antibiotic resistant bacteria accelerator to advance the development of its antibiotic immunotherapy cd for the treatment of lifethreatening multidrug resistant mdr gramnegative bacterial infections cd is the first development candidate to be generated by cidara’s novel cloudbreak immunotherapy discovery platform designed to create compounds that direct a patient’s immune cells to attack and eliminate bacterial fungal or viral pathogens first quarter  financial results • cash cash equivalents and shortterm investments totaled  million as of march   compared with  million as of december   management continues to expect cash burn of  to  million for  • research and development expenses were  million for the three months ended march   compared to  million for the same period in  the increase was primarily attributable to clinical development activities for cd • general and administrative expenses were  million for the three months ended march   compared to  million for the same period in  the increase was primarily due to higher personnelrelated costs to support the growth of operating activities • net loss for the three months ended march   was  million compared to a net loss of  million for the first quarter of  • as of april   cidara had  common shares outstanding about cidara therapeutics cidara is a clinicalstage biotechnology company focused on developing new antiinfectives that have the potential to transform the standard of care and save or improve patients’ lives the company is currently advancing its novel echinocandin antifungal cd iv through phase  and developing cd its bispecific antibiotic immunotherapy for the treatment of multidrug resistant gramnegative bacterial infections cd iv has improved pharmacokinetics compared to existing echinocandins and has the potential for expanded utility across patient settings cd iv is the only onceweekly product candidate in development for the treatment and prevention of lifethreatening invasive fungal infections cd is the first drug candidate selected from cidara’s novel cloudbreak™ platform and is designed to specifically direct a patient’s immune cells to attack and kill bacterial pathogens cidara recently received a grant for up to  million from carbx combating antibiotic resistant bacteria accelerator to advance the development of cd cidara is headquartered in san diego california for more information please visit wwwcidaracom forwardlooking statements statements contained in this press release regarding matters that are not historical facts are forwardlooking statements within the meaning of the private securities litigation reform act of  because such statements are subject to risks and uncertainties actual results may differ materially from those expressed or implied by such forwardlooking statements such statements include but are not limited to statements regarding the effectiveness safety and other attributes of cd and cd and other potential product candidates including the potential for these compounds to successfully treat or prevent fungal or bacterial infections including those caused by resistant pathogens and potentially transform the way infectious diseases are treated and the potential for the cloudbreak platform to result in future drug candidates risks that contribute to the uncertain nature of the forwardlooking statements include the success and timing of cidara’s preclinical studies and clinical trials regulatory developments in the united states and foreign countries changes in cidara’s plans to develop and commercialize its product candidates cidara’s ability to obtain additional financing cidara’s ability to obtain and maintain intellectual property protection for its product candidates and the loss of key scientific or management personnel these and other risks and uncertainties are described more fully in cidara’s form k most recently filed with the united states securities and exchange commission all forwardlooking statements contained in this press release speak only as of the date on which they were made cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made cidara therapeutics inc condensed consolidated balance sheets march   december   in thousands unaudited assets cash cash equivalents and shortterm investments     other current assets   noncurrent assets   total assets     liabilities and stockholders equity total liabilities     stockholders equity   total liabilities and stockholders equity     cidara therapeutics inc condensed consolidated statements of operations three months ended march      in thousands except share and per share data unaudited   unaudited operating expenses research and development     general and administrative   total operating expenses   loss from operations     other income expense interest income expense net —  total other income expense —  net loss       basic and diluted net loss per share       shares used to compute basic and diluted net loss per share   investor contact robert h uhl westwicke partners llc managing director   robertuhlwestwickecom media contact christy curran sam brown inc   christycurransambrowncom  cidara therapeutics inc  nancy ridge dr san diego ca biological products  mapquest cidara therapeutics inc  nancy ridge dr san diego ca  reviews   website menu  reservations make reservations order online tickets tickets see availability nearby directions  sponsored topics see a problem let us know legal help cdtx stock quote  cidara therapeutics inc common stock price  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search home  quotes  cdtx cidara therapeutics inc common stock quote  summary data cdtx        get cdtx alerts delayed  data as of jul      find a broker to begin trading cdtx now exchangenasdaq industry health care community rating cdtx     edit symbol list symbol lookup real time nls trade reporting flashquotes infoquotes summary quote charts interactive charts premarket charts after hours charts revenue  eps summary company financials  view competitors  short interest company news press releases company news press releases sentiment analyst stock research stock report sec filings  holdingsinsider summary  institutional holdings  insider form  equity options premarket quotes after hours quotes company research  stockconsultant stock comparison  guru analysis annual report historical quotes call transcripts dividend history lynch analysis graham analysis validea momentum analysis fool analysis dreman analysis zweig analysis fisher analysis oshaughnessy analysis etf detail etf profile comparison charts symbol list views flashquotes infoquotes stock details summary quote realtime quote after hours quote premarket quote historical quote option chain charts basic chart interactive chart company news company headlines press releases market stream stock analysis analyst research guru analysis stock report competitors stock consultant stock comparison fundamentals call transcripts annual report income statement revenueeps sec filings short interest dividend history holdings ownership summary institutional holdings insiderssec form  closex edit symbol list enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages go now clear list dont know the stock symbol use the symbol lookup tool alphabetize the sort order of my symbols closex   symbol lookup closex investing just got easier… sign up now to become a nasdaqcom member and begin receiving instant notifications when key events occur that affect the stocks you follow access now  save stocks news pricecharts tradehistory annual report earningsreport date dynamic quotes turn off best bidask best bid is the highest price currently being offered for a block of stock best ask is the lowest price currently being asked for a block of stock na  na  year target  todays high low todays high the highest sales price the stock has achieved during the regular trading hours the intraday high todays low the lowest sales price the stock has fallen to during the regular trading hours the intraday low      share volume share volume is the number of shares of the stock traded on the listing exchange during current trading hours it does not include after hours volume   day avg daily volume this is the average share volume for the past  trading days for nasdaq stocks and  trading days for nonnasdaq stocks this field allows you to compare todays trading to the average daily volume  previous close previous close is the previous trading days last reported trade price during official trading hours    week highlow  week high is the highest sales price the stock has achieved during the regular trading hours during the most recent  week period  week low is the lowest sales price the stock has fallen to during the regular trading hours during the most recent  week period      market cap “market capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent it does not include securities convertible into the common equity securities “market capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities as applicable nasdaq does not use this value to determine compliance with the listing requirements   pe ratio pe ratio is a statistic calculated by dividing the price of a stock by the reported actual earnings per share of the issuing firm not the same as the projected pe ratio it is also called the multiple ne forward pey a widely used stock evaluation measure for a security the priceearnings ratio is given by dividing the last sale price by the average eps earnings per share estimate for the specified fiscal time period the forward pe refers to the value for the next full year ne earnings per share eps the eps listed on our infoquote and summary quote page is mos rolling eps represents the portion of a companys profit allocated to each outstanding share of common stock net income reported or estimated for a period of time is divided by the total number of shares outstanding tso during that period see growth rate measures for eps our vendors methodology for the eps on the infoquote and summary quote pages follows the eps used by the majority of the analysts following the stock in many cases this is ebitda eps   annualized dividend na ex dividend date the data is based on historical exdividend data  doesn’t include upcoming values visit the dividend history page to see the upcoming dividend information na dividend payment date na current yield indicated yield represents annual dividends divided by current stock price the data is based on historical exdividend data  doesn’t include upcoming values visit the dividend history page to see the upcoming dividend information   beta beta is a volatility measurement of a stock mutual fund or etf versus a comparable benchmark like the sp  stock index a stock fund or etf with a higher beta than the sp  will rise or fall to a greater degree in contrast a stock fund or etf with a low beta will rise or fall less  nasdaq official open price nasdaq official opening price this process identifies the nasdaqspecific opening prices for nasdaqlisted issues   date of open price date of open price this field refers to the date the nasdaq official open price was disseminated for a given stock it is possible that the date will not be from the current trading day this indicates that the stock didnt trade on nasdaq during the current trading day the nasdaq official open price is updated only when the stock is traded on nasdaq jul   nasdaq official close price nasdaq official closing price nocp is a process for identifying the nasdaq marketspecific closing price for nasdaqlisted issues   date of close price this field refers to the date the nocp was disseminated for a given stock it is possible that the date will not be from the prior day this indicates that the stock didnt trade on nasdaq on the prior day the nocp is updated only when the stock is traded on nasdaq jul   community sentiment intraday chart d m m m more charting company description as filed with the sec we are a biotechnology company focused on the discovery development and commercialization of novel antiinfectives for the treatment of diseases that are inadequately addressed by current standard of care therapies we are developing a balanced pipeline of product and development candidates with an initial focus on serious fungal and bacterial infections our lead product candidate is cd iv an intravenous formulation of a novel echinocandin cd iv is being developed as a onceweekly highexposure therapy for the treatment and prevention of serious invasive fungal infections in addition we are developing cd our bispecific antimicrobial immunotherapy for the treatment of multidrugresistant bacterial infections cd is the first development candidate selected from our proprietary cloudbreaktm platform which is designed to create compounds that direct a patients immune system to attack and eliminate bacterial fungal or viral pathogens   more    risk grade where does cdtx fit in the risk graph news for cdtx gainers  losers of july  vstm bgne alrn txmd ocul   pm  rtt news gainers  losers of june  anth nk omer gtxi gnmk   pm  rtt news scynexis another buy opportunity on the recent pullback   am  seeking alpha is a surprise coming for cidara therapeutics cdtx this earnings season   am  zackscom perrigo company prgo q earnings disappointment in store   am  zackscom  subscribe more cdtx news  commentary read cdtx press releases consensus recommendation analyst info annual eps est  quarterly eps est  peg ratio  mean recommendation  data is provided by zacks investment research view all view summary closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft cidara therapeutics inc  health  content results aol search skip over navigation search the web web web images images search web results  search several engines  searchallcom ad · wwwsearchallcom​results search for what youre looking for with s of results at searchall crispr therapeutics info  search for crispr therapeutics ad · alothomecom​crispr​therapeutics find crispr therapeutics results on alothomecom browse top listings online similase at amazon  save on similase ad · wwwamazoncom​health save on similase free day shipping w amazon prime health  personal care nutrition  wellness baby  child care silk therapeutics inc  search for silk therapeutics inc ad · downloadsearchcnetcom search for silk therapeutics inc find the top results here all that you need business companies financial news your search for cidara therapeutics inc returned no results search web results  search several engines  searchallcom ad · wwwsearchallcom​results search for what youre looking for with s of results at searchall crispr therapeutics info  search for crispr therapeutics ad · alothomecom​crispr​therapeutics find crispr therapeutics results on alothomecom browse top listings online similase at amazon  save on similase ad · wwwamazoncom​health save on similase free day shipping w amazon prime health  personal care nutrition  wellness baby  child care silk therapeutics inc  search for silk therapeutics inc ad · downloadsearchcnetcom search for silk therapeutics inc find the top results here all that you need business companies financial news searches related tocidara therapeutics inc cidara stock price cidara stock cara therapeutics inc cidara therapeutics san diego cidara pharmaceuticals cidara cara therapeutics news cidara ipo related searches cidara stock price cidara stock cara therapeutics inc cidara therapeutics san diego cidara pharmaceuticals cidara cara therapeutics news cidara ipo search the web  aol inc all rights reservedprivacy   terms of use   preferences   contact us   powered by bing™ wowcom  part of the aol search network cidara therapeutics press enter to begin your search home about about cidara management team board of directors partnership inquiries careers pipeline overview cd iv cd publications cloudbreak™ opportunity systemic fungal infections systemic candida infections invasive aspergillosis gramnegative bacterial infections newsroom investors overview financials stock information corporate governance news  events shareholder services new hope for serious infections cidara is a clinicalstage biotechnology company focused on the development of new antiinfectives that have the potential to transform the standard of care and save or improve patients’ lives our pipeline includes cd iv a longacting echinocandin antifungal and cd our lead antimicrobial candidate for multidrug resistant bacteria generated by our cloudbreak™ immunotherapy discovery platform about cidara  drug candidates recent news and insights jeff stein and others explore the antifungal public health crisis and the need for nextgeneration antifungal treatments at the bio international convention cidara to participate in antiinfectives panel discussion at the  infectious diseases summit  july   cidara to participate in the  bio international convention  june   view all news releases our mission cidara seeks to save or improve patients’ lives through the development of antiinfectives that transform the standard of care our initial portfolio is comprised of proprietary product candidates for the treatment of serious fungal and bacterial infections there is an urgent and growing need not only for improved antiinfectives but also for entirely new therapeutic approaches to treat and prevent fungal bacterial and viral pathogens particularly those that are increasingly resistant to available treatments cd iv cd iv is a novel echinocandin antifungal with potent activity against candida aspergillus and pcp we are developing cd iv for once weekly use in treatment and prophylaxis we are currently conducting an international phase  trial strive in candidemia and invasive candidiasis learn more cloudbreak™  cd cloudbreak is a proprietary immunotherapy discovery platform that has the potential to do for infectious disease what immunotherapy has done for cancer cd is our lead cloudbreak candidate intended to direct a patient’s immune cells to attack bacterial infections cd  cloudbreak get important news and updates by email about us cidara is a clinicalstage biotechnology company focused on developing new antiinfectives and immunotherapies that have the potential to transform the standard of care and save or improve patients lives learn more  recent newscidara therapeutics to participate in antiinfectives panel discussion at the  infectious diseases summit july  cidara therapeutics to participate in the  bio international convention june   navigationabout cidara cd iv cd cloudbreak™ platform publications investors contact contact us cidara therapeutics inc  nancy ridge drive suite  san diego ca  tel   email infocidaracom   cidara therapeutics inc  terms of use  privacy policy quick linksabout cidara cd iv cd cloudbreak™ platform publications investors contact tweets by cidarathera bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one